Study of OM336 for people with active autoimmune diseases
Part of Bones, joints & muscles, Brain & nervous system clinical trials.
This trial tests a new treatment called OM336 for people with active autoimmune diseases that have not improved after at least two other treatments. The goal is to see if OM336 can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with an active autoimmune disease that is seropositive (meaning certain antibodies are found in your blood).
- Your disease has come back or not gotten better after at least two past or current treatments.
- You weigh at least 50 kilograms (about 110 pounds).
- You are willing to follow the study rules and procedures.
- You have not had a treatment that targets BCMA before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called OL-108 for people with certain autoimmune diseases (lupus, myositis, scleroderma, or vasculitis) that have come back or not responded to standard treatments. The goal is to see if it's safe and if it can help control the disease.
This early-phase study tests a new drug called CC312 in patients with certain autoimmune diseases like lupus, myositis, scleroderma, rheumatoid arthritis, immune thrombocytopenia, or autoimmune hemolytic anemia. The goal is to see if it's safe and how the body handles it.
This trial tests a new drug called OM336 for people whose immune system is attacking their own blood cells, causing low counts. It is for those who have already tried at least one treatment that did not work well or stopped working.
This trial is testing an experimental drug for safety in people with certain autoimmune diseases—like myositis, scleroderma, or Sjögren's disease—as well as in healthy volunteers. It aims to find out if the drug is safe enough to study further.
This study tests a new drug called CM336 for people with primary Sjögren's syndrome (an autoimmune disease affecting salivary and tear glands). The drug is designed to help reduce disease activity in patients who haven't responded well to previous treatments.
This study tests a new drug called CM336 for people with autoimmune blistering diseases. The drug is designed to calm the immune system and reduce blistering, aiming to improve skin health.
Hear when a new Sjogrens Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.